Cited by 244Pharmaceutical studies and practicesStatistical Methods in Clinical TrialsPharmacogenetics and Drug Metabolism

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance

Open access

Jamei, Masoud·2016·Current Pharmacology Reports

DOI 10.1007/s40495-016-0059-9PMC PMC4856711

Open this paper in CoChat — free account Open PDF

Abstract

There is a renewed surge of interest in applications of physiologically-based pharmacokinetic (PBPK) models by the pharmaceutical industry and regulatory agencies. Developing PBPK models within a systems pharmacology context allows separation of the parameters pertaining to the animal or human body (the system) from that of the drug and the study design which is essential to develop generic drug-independent models used to extrapolate PK/PD properties in various healthy and patient populations. This has expanded the classical paradigm to a 'predict-learn-confirm-apply' concept. Recently, a number of drug labels are informed by simulation results generated using PBPK models. These cases show that either the simulations are used in lieu of conducting clinical studies or have informed the drug label that otherwise would have been silent in some specific situations. It will not be surprising to see applications of these models in implementing precision dosing at the point of care in the near future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s40495-016-0059-9

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Rodgers, T., & Rowland, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20502 · Cited by 949
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification
Sager, J. E., Yu, J., Ragueneau, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 541
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami‐Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 533
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
Zhao, P., Zhang, L., Grillo, J. A., Liu, Q., Bullock, J. M., Moon, Y. J., Song, P., Brar, S. S., Madabushi, R., Wu, T. C., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.298 · Cited by 524
Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective
Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488
A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates
Jamei, M., Dickinson, G. L., & Rostami‐Hodjegan, A. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.53 · Cited by 377
Self-citation
Physiologically Based Pharmacokinetics Joined with In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology
Rostami-Hodjegan, A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.65 · Cited by 331
Prediction of Pharmacokinetics Prior to In Vivo Studies. II. Generic Physiologically Based Pharmacokinetic Models of Drug Disposition
Poulin, P., & Theil, F. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10128 · Cited by 303
Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK
Wagner, C., Zhao, P., Pan, Y., Hsu, V, Grillo, J., Huang, S., & Sinha, V (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.33 · Cited by 276

Flagged first, then by citations

Show all 41 references

Sorted by citations

Items 101–200 of 244

In-Depth Analysis of Physiologically Based Pharmacokinetic (PBPK) Modeling Utilization in Different Application Fields Using Text Mining Tools
Krstevska, A., Djuriš, J., Ibric, S. R., & Cvijić, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010107 · Cited by 20
Physiologically‐Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV
Stader, F., Courlet, P., Decosterd, L. A., Battegay, M., & Marzolini, C. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2178 · Cited by 20
Placental transfer and vascular effects of pharmaceutical drugs in the human placenta ex vivo: A review
van Hove, H., Mathiesen, L., Freriksen, J. J. M., Vähäkangas, K., Colbers, A. P. H., Brownbill, P., & Greupink, R. (2022) · Placenta · doi:10.1016/j.placenta.2022.03.128 · Cited by 19
Physiologically Based Pharmacokinetics Modeling in the Neonatal Population—Current Advances, Challenges, and Opportunities
Dinh, J., Johnson, T. N., Grimstein, M., & Lewis, T. R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112579 · Cited by 19
A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application
Tylutki, Z., & Polak, S. (2017) · Scientific Reports · doi:10.1038/srep39494 · Cited by 18
Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART
Roberts, O. L., Rajoli, R. K. R., Back, D. J., Owen, A., Darin, K. M., Fletcher, C. V., Lamorde, M., Scarsi, K. K., & Siccardi, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx515 · Cited by 18
Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
Humphries, H., Almond, L. M., Berg, A. K., Gardner, I. B., Hatley, O. J. D., Pan, X., Small, B. G., Zhang, M., Jamei, M., & Romero, K. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12707 · Cited by 18
Self-citation
Development of quantitative systems pharmacology and toxicology models within consortia: experiences and lessons learned through DILIsym development
Howell, B. A., Siler, S. Q., Barton, H. A., Joshi, E., Cabal, A., Eichenbaum, G. M., & Watkins, P. B. (2016) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2017.04.001 · Cited by 17
The Yin–Yang of CYP3A4: a Bayesian meta-analysis to quantify inhibition and induction of CYP3A4 metabolism in humans and refine uncertainty factors for mixture risk assessment
Quignot, N., Więcek, W., Amzal, B., & Dorne, J. L. C. M. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2325-6 · Cited by 17
Translational learning from clinical studies predicts drug pharmacokinetics across patient populations
Krauß, M., Hofmann, U., Schafmayer, C., Igel, S., Schlender, J., Mueller, C., Brosch, M., von Schoenfels, W., Erhart, W., Schuppert, A., et al. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0012-5 · Cited by 17
Gene expression databases for physiologically based pharmacokinetic modeling of humans and animal species
Cordes, H., & Rapp, H. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12904 · Cited by 16
Saliva versus Plasma Therapeutic Drug Monitoring of Gentamicin in Jordanian Preterm Infants. Development of a Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class II Drugs of Salivary Excretion Classification System
Idkaidek, N., Hamadi, S., Bani-Domi, R., Al-Adham, I. S. I., Alsmadi, M. M., Al-Awaysheh, F., Aqrabawi, H., Al‐Ghazawi, A., & Rabayah, A. (2020) · Drug Research · doi:10.1055/a-1233-3582 · Cited by 16
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making
Djebli, N., Buchheit, V., Parrott, N. J., Guerini, E., Cleary, Y., Fowler, S. M., Frey, N., Yu, L. J., Mercier, F., Phipps, A., et al. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00714-z · Cited by 16
Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease
Vasilogianni, A., El‐Khateeb, E., Al‐Majdoub, Z. M., Alrubia, S., Rostami‐Hodjegan, A., Barber, J., & Achour, B. (2022) · Journal of Proteomics · doi:10.1016/j.jprot.2022.104601 · Cited by 17
Where Do PBPK Models Stand in Pharmacometrics and Systems Pharmacology?
Jamei, M. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12493 · Cited by 15
Self-citation
Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions
Statelova, M., Holm, R., Fotaki, N., Reppas, C. I., & Vertzoni, M. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00504-6 · Cited by 15
Informing Development of Bispecific Antibodies Using Physiologically Based Pharmacokinetic‐Pharmacodynamic Models: Current Capabilities and Future Opportunities
Gibbs, J. P., Yuraszeck, T. M., Biesdorf, C., Xu, Y., & Kasichayanula, S. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1706 · Cited by 15
Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I–IV drugs
Melillo, N., Aarons, L. J., Magni, P., & Darwich, A. S. (2018) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-018-9615-8 · Cited by 16
Building in-house PBPK modelling tools for oral drug administration from literature information
Grandoni, S., Cesari, N., Brogin, G., Puccini, P., & Magni, P. (2019) · ADMET & DMPK · doi:10.5599/admet.638 · Cited by 17
Prediction of Drug–Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model
Willemin, M., Zannikos, P., Mannens, G., Zwart, L. D., & Snoeys, J. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01123-4 · Cited by 15
Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3A drug–drug interaction potential in patients with advanced malignancies
Ou, Y. C., Xu, Y., Gore, L., Harvey, R. D., Mita, A. C., Papadopoulos, K. P., Wang, Z., Cutler, R. E., Pinchasik, D. E., & Tsimberidou, A. M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13817 · Cited by 14
Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview
Jia, Q., He, Q., Li, Y., Li, M., Lin, J., Tang, Z., Zhu, X., & Xiang, X. (2022) · Molecules · doi:10.3390/molecules27248670 · Cited by 13
Modelling Based Approaches to Support Generic Drug Regulatory Submissions-Practical Considerations and Case Studies
Karnati, P., Murthy, A. N., Gundeti, M., & Ahmed, T. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00831-4 · Cited by 13
Apixaban and rivaroxaban's physiologically‐based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side
Terrier, J. E., Gaspar, F., Gosselin, P., Raboud, O., Lenoir, C., Rollason, V., Csajka, C., Samer, C. F., Fontana, P., Daali, Y., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13036 · Cited by 13
Physiologically-Based Pharmacokinetic Modeling for Drugs Cleared by Non-Cytochrome P450 Enzymes: State-of-the-Art and Future Perspectives
Ozbey, A. C., Fowler, S. M., Leys, K., Annaert, P., Umehara, K., & Parrott, N. J. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001487 · Cited by 13
The Interplay of Permeability, Metabolism, Transporters, and Dosing in Determining the Dynamics of the Tissue/Plasma Partition Coefficient and Volume of Distribution—A Theoretical Investigation Using Permeability-Limited, Physiologically Based Pharmacokinetic Modeling
Gaohua, L., Zhang, M., Sychterz, C. J., Chang, M., & Schmidt, B. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216224 · Cited by 13
Beyond the basics: A deep dive into parameter estimation for advanced PBPK and QSP models
Toshimoto, K. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101011 · Cited by 13
Pediatric Physiologically Based Pharmacokinetic Model Development: Current Status and Challenges
Lin, W., Yan, J., Heimbach, T., & He, H. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0162-1 · Cited by 13
Reduced order modeling and analysis of the human complement system
Sagar, A., Dai, W., Minot, M., LeCover, R., & Varner, J. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187373 · Cited by 13
Population variability in animal health: Influence on dose‐exposure‐response relationships: Part II : Modelling and simulation
Martinez, M. N., Gehring, R., Mochel, J. P., Pade, D., & Pelligand, L. (2018) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12666 · Cited by 13
A Physiologically Based Pharmacokinetic Model to Predict Systemic Ondansetron Concentration in Liver Cirrhosis Patients
Alqahtani, F., Alruwaili, A., Alasmari, M. S., Almazroa, S. A., Alsuhaibani, K. S., Rasool, M. F., Alruwaili, A. F., & Alsanea, S. (2023) · Pharmaceuticals · doi:10.3390/ph16121693 · Cited by 12
Application of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in Japanese.
Suzuki, M., Tse, S. Y. H., Hirai, M., & Kurebayashi, Y. (2017) · Europe PMC (PubMed Central) · doi:10.24546/81009836 · Cited by 12
Selection and Qualification of Simplified QSP Models When Using Model Order Reduction Techniques
Hasegawa, C., & Duffull, S. B. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0170-9 · Cited by 12
Clinical Applications of Physiologically Based Pharmacokinetic Modeling: Perspectives on the Advantages and Challenges
Emoto, C., McPhail, B. T., & Fukuda, T. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000714 · Cited by 12
In‐depth analysis of patterns in selection of different physiologically based pharmacokinetic modeling tools: Part I – Applications and rationale behind the use of open source‐code software
Rajput, A. J., Aldibani, H. K. A., & Rostami‐Hodjegan, A. (2023) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2357 · Cited by 12
Physiologically based toxicokinetic models and in silico predicted partition coefficients to estimate tetrachlorodibenzo-p-dioxin transfer from feed into growing pigs
Savvateeva, D., Numata, J., Pieper, R., Schafft, H. A., Lahrssen‐Wiederholt, M., & Bulik, S. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02617-0 · Cited by 12
Toxicokinetics in Risk Evaluations
Punt, A. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00061 · Cited by 12
Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study
Bettonte, S., Berton, M., Stader, F., Battegay, M., & Marzolini, C. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae171 · Cited by 11
A Bayesian framework for virtual comparative trials and bioequivalence assessments
Bois, F. Y., & Brochot, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1404619 · Cited by 11
Research Landscape of Physiologically Based Pharmacokinetic Model Utilization in Different Fields: A Bibliometric Analysis (1999–2023)
Wang, X., Wu, J., Ye, H., Zhao, X., & Zhu, S. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03676-4 · Cited by 11
Pharmacokinetics of Chlorin e6-Cobalt Bis(Dicarbollide) Conjugate in Balb/c Mice with Engrafted Carcinoma
Volovetsky, A. B., Sukhov, V., Владимировна, Б. И., Dudenkova, V. V., Shilyagina, N. Y., Feofanov, A. V., Efremenko, A. V., Grin, M. A., Миронов, А. Ф., Sivaev, I. B., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122556 · Cited by 11
Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification
Tylutki, Z., Mendyk, A., & Polak, S. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.11.012 · Cited by 11
Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
Sun, L., Barter, Z. E., Moltke, L. L. V., & Yeo, K. R. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12675 · Cited by 11
Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro
Roberts, O. L., Khoo, S., Owen, A., & Siccardi, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01776-16 · Cited by 11
Insights into DPI sensitivity to humidity: An integrated in-vitro-in-silico risk-assessment
Radivojev, S., Pinto, J. T., Fröhlich, E., & Paudel, A. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.05.047 · Cited by 11
Incorporation and Performance Verification of Hepatic Portal Blood Flow Shunting in Minimal and Full PBPK Models of Liver Cirrhosis
Small, B. G., Hatley, O. J. D., Jamei, M., Gardner, I. B., & Johnson, T. N. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3032 · Cited by 10
Self-citation
Potential and challenges in application of physiologically based pharmacokinetic modeling in predicting diarrheal disease impact on oral drug pharmacokinetics
Zhang, C., & Arnold, S. L. M. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000964 · Cited by 10
Physiologically Based Oral Absorption Modelling to Study Gut-Level Drug Interactions
Chung, J., & Kesisoglou, F. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.08.015 · Cited by 10
A multilevel object-oriented modelling methodology for physiologically-based pharmacokinetics (PBPK): Evaluation with a semi-mechanistic pharmacokinetic model
Reig-López, J., Merino‐Sanjuán, M., Sanjuan, V. M., & Prado-Velasco, M. (2020) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2020.105322 · Cited by 10
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL ‐6 levels following administration of the T‐cell bispecific engager glofitamab
Djebli, N., Parrott, N. J., Jaminion, F., O’Jeanson, A., Guerini, E., & Carlile, D. J. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13091 · Cited by 10
Assessing interindividual variability by Bayesian-PBPK modeling
Krauß, M., & Schuppert, A. (2016) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2017.08.001 · Cited by 10
Machine learning-based prediction of pharmacokinetic parameters for individualized drug dosage optimization
Mtshali, S., & Jacobs, B. A. (2024) · International Journal of Information Technology · doi:10.1007/s41870-024-02314-x · Cited by 9
Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment
Quignot, N., Więcek, W., Lautz, L. S., Dorne, J. L. C. M., & Amzal, B. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.11.016 · Cited by 9
Are body surface area based estimates of liver volume applicable to children with overweight or obesity? An in vivo validation study
Hosey‐Cojocari, C., Chan, S., Friesen, C. S., Robinson, A. L., Williams, V., Swanson, E., O'Toole, D., Radford, J., Mardis, N., Johnson, T., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13059 · Cited by 9
Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan
Hong, Y., Ishizuka, T., Watanabe, A., Tachibana, M., Lee, M. A., Ishizuka, H., LaCreta, F. P., & Abutarif, M. A. (2021) · Clinical and Translational Science · doi:10.1111/cts.13082 · Cited by 9
Representing Normal and Abnormal Physiology as Routes of Flow in ApiNATOMY
de Bono, B., Gillespie, T., Surles-Zeigler, M. C., Kokash, N., Grethe, J. S., & Martone, M. E. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.795303 · Cited by 7
In Silico Pharmacology for Evidence-Based and Precision Medicine
Spanakis, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031014 · Cited by 9
Transformative trends: A comprehensive review on role of artificial intelligence in healthcare and pharmaceutical research
Bhabad, S., Lamkhade, D., Koyate, S., Karanjkhele, K., Kale, V., & Doke, R. R. (2023) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2023.034 · Cited by 8
Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper
Sawant‐Basak, A., Urva, S., Mukker, J. K., Haertter, S., Mariano, D., Parasrampuria, D. A., Goteti, K., Singh, R. S. P., Chiney, M. S., Liao, M. Z., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3350 · Cited by 8
Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology
Leow, J. W. H., Tang, L. W. T., & Chan, E. C. Y. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2022.05.003 · Cited by 8
Predicting Hydroxychloroquine Clearance in Healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach
Alqahtani, F., Asiri, A., Zamir, A., Rasool, M. F., Alali, A. S., Alsanea, S., & Walbi, I. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041250 · Cited by 8
Safety of medicines during breastfeeding – from case report to modeling: a contribution from the ConcePTION project
Cardoso, E., Guidi, M., Nauwelaerts, N., Nordeng, H., Teil, M., Allegaert, K., Smits, A., Gandia, P., Edginton, A. N., Ito, S., et al. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2221847 · Cited by 8
The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel
Alsmadi, M. M., Jaradat, M. M., Obaidat, R., Alnaief, M., Tayyem, R. F., & Idkaidek, N. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02627-3 · Cited by 8
QSAR/QSPR Modeling in the Design of Drug Candidates with Balanced Pharmacodynamic and Pharmacokinetic Properties
Lambrinidis, G., Tsopelas, F. N., Giaginis, C., & Tsantili‐Kakoulidou, A. (2017) · Challenges and advances in computational chemistry and physics · doi:10.1007/978-3-319-56850-8_9 · Cited by 7
The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall
Darwich, A. S., Burt, H. J., & Rostami‐Hodjegan, A. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.02.017 · Cited by 8
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region
Alasmari, M. S., Albusaysi, S., Elhefnawy, M. E., Ali, A. M., Altigani, K., Almoslem, M., Alharbi, M., Alghamdi, J., & Alsultan, A. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102207 · Cited by 7
Double Peaking Phenomena in Pharmacokinetic Disposition Revisited
Yousef, M., Brocks, D. R., Löbenberg, R., & Davies, N. M. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01559-4 · Cited by 7
The Promise of Animal Testing Alternatives at the U.S. Food and Drug Administration and National Institutes of Health
Tieghi, R. S., Høeg, T. B., Makary, M. A., & Kleinstreuer, N. (2025) · NEJM AI · doi:10.1056/aipc2500587 · Cited by 7
Comparisons of PK-Sim and R program for physiologically based pharmacokinetic model development for broiler chickens and laying hens: meloxicam as a case study
Zhang, Z., Tell, L. A., & Lin, Z. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf016 · Cited by 7
Integrating in vitro chemical transplacental passage into a generic PBK model: A QIVIVE approach
Fragki, S., Hoogenveen, R. T., van Oostrom, C., Schwillens, P., Piersma, A. H., & Zeilmaker, M. J. (2021) · Toxicology · doi:10.1016/j.tox.2021.153060 · Cited by 8
Advancing tuberculosis drug regimen development through innovative quantitative translational pharmacology methods and approaches
Hanna, D. L., Romero, K., & Schito, M. L. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.10.008 · Cited by 7
Incorporating Epigenetics Into a Risk Assessment Framework
Cote, I., Vandenberg, J. J., Druwe, I. L., & Angrish, M. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812433-8.00013-7 · Cited by 7
Physiologically based pharmacokinetic modelling of treprostinil after intravenous injection and extended‐release oral tablet administration in healthy volunteers: An extrapolation to other patient populations including patients with hepatic impairment
Wu, X., Zhang, X., Xu, R., Shaik, I. H., & Venkataramanan, R. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14966 · Cited by 7
Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants
Terrier, J. E., Daali, Y., Fontana, P., Csajka, C., & Reny, J. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00792-y · Cited by 8
History and Evolution of Innovations in Clinical Pharmacology
Lesko, L. J., & van der Graaf, P. H. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70048 · Cited by 7
Development and verification of mechanistic vaginal absorption and metabolism model to predict systemic exposure after vaginal ring and gel application
Thakur, K., Telaprolu, K. C., Paterson, D., Salem, F., Arora, S., & Polak, S. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16029 · Cited by 6
Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers
Reig-López, J., Cuquerella-Gilabert, M., Bandín‐Vilar, E., Merino‐Sanjuán, M., Sanjuan, V. M., & García‐Arieta, A. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114293 · Cited by 6
Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N‐desbutyldronedarone: Application to prospective simulation of complex drug–drug interaction with rivaroxaban
Leow, J. W. H., Ang, X. J., & Chan, E. C. Y. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15670 · Cited by 6
Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
Litjens, C. H. C., Verscheijden, L. F. M., Svensson, E. M., van den Broek, P. H. H., van Hove, H., Koenderink, J. B., Rüssel, F. G. M., Aarnoutse, R. E., & Brake, L. H. M. T. (2023) · Antibiotics · doi:10.3390/antibiotics12040702 · Cited by 6
On the Verge of Impossibility: Accounting for Variability Arising from Permutations of Comorbidities that Affect the Fate of Drugs in the Human Body
Rostami‐Hodjegan, A., & Achour, B. (2023) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-29541-6_6 · Cited by 7
Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
Litjens, C. H. C., Verscheijden, L. F. M., Bolwerk, C., Greupink, R., Koenderink, J. B., van den Broek, P. H. H., van den Heuvel, J. J. M. W., Svensson, E. M., Boeree, M. J., Magis-Escurra, C., et al. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1972 · Cited by 6
A novel physiologically based pharmacokinetic model of rectal absorption, evaluated and verified using clinical data on 10 rectally administered drugs
Dancik, Y., Mittapelly, N., Puttrevu, S. K., & Polak, S. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123273 · Cited by 5
Building a Predictive PBPK Model for Human OATP Substrates: a Strategic Framework for Early Evaluation of Clinical Pharmacokinetic Variations Using Pitavastatin as an Example
Liang, X., Koleske, M. L., Yang, J., & Lai, Y. (2024) · The AAPS Journal · doi:10.1208/s12248-023-00882-7 · Cited by 5
Clinical significance of the rivaroxaban–dronedarone interaction: insights from physiologically based pharmacokinetic modelling
Hügl, B. J., Horlitz, M., Fischer, K., & Kreutz, R. H. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead004 · Cited by 5
Next-generation experimental and computational strategies for drug-drug interaction prophecy
Kanukolanu, A., Nalla, L. V., & Gajula, S. N. R. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100150 · Cited by 4
Humans Vary, So Cardiac Models Should Account for That Too!
Wiśniowska, B., Tylutki, Z., & Polak, S. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00700 · Cited by 4
Revisiting the role of gut wall in the fate of orally administered drugs: Why now and to what effect?
Rostami‐Hodjegan, A., Tamai, I., & Pang, K. S. (2017) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2071 · Cited by 4
EFFECT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ON HEPATIC DRUG METABOLISM ENZYMES IN HUMAN
Jamwal, R. (2018) · doi:10.23860/diss-jamwal-rohitash-2018 · Cited by 4
Biological Monitoring of Exposure to Industrial Chemicals
Hopf, N. B., & Fustinoni, S. (2021) · Wiley eBooks · doi:10.1002/0471435139.hyg042.pub3 · Cited by 4
Enabling transparent toxicokinetic modeling for public health risk assessment
Davidson-Fritz, S. E., Ring, C., Evans, M. V., Schacht, C. M., Chang, X., Breen, M., Honda, G. S., Kenyon, E. M., Linakis, M. W., Meade, A. E., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321321 · Cited by 3
Closing the loop: human-augmented, mechanistically enhanced AI for proactive management of drug–drug interactions
Spanakis, M., Pauw, A. D., Brumer, M., Symvoulakis, E. K., & Loof, H. D. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1767646 · Cited by 3
Breadth of Pharmacology Modeling: Fundamentals of Pharmacokinetics, Pharmacodynamics, and Mechanistic Modeling
Mager, D. E. (2025) · Handbook of experimental pharmacology · doi:10.1007/164_2025_746 · Cited by 3
Physiologically Based Pharmacokinetic (PBPK) Modeling and Pharmacokinetic Pharmacodynamic (PKPD) Modelling
Varnekar, S., Sohal, M., Tikale, N., Ruchitha Reddy, S., Bose, A., Pawar, S., & Kurkute, P. (2025) · Springer eBooks · doi:10.1007/978-981-96-4154-3_14 · Cited by 3
Physiologically-based pharmacokinetic modeling after drug inhalation
Himstedt, A., Bäckman, P., & Borghardt, J. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814974-4.00009-2 · Cited by 3
Regulatory Requirements and Applications of Physiologically Based Pharmacokinetic Models
Cuquerella-Gilabert, M., Merino‐Sanjuán, M., García‐Arieta, A., Sanjuan, V. M., & Reig-López, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-50419-8_9 · Cited by 3
Matrix Approach Assessment of Cabotegravir Drug–Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling
Tracey, H., Bate, S. T., Ford, S. L., Patel, P., Bloomer, J. C., Patel, A. H., & Taskar, K. S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040531 · Cited by 3
A latent variable approach to account for correlated inputs in global sensitivity analysis
Melillo, N., & Darwich, A. S. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09764-x · Cited by 3
Analysis of biomonitoring data to assess employer compliance with OSHA's permissible exposure limits for air contaminants
Tustin, A. W., & Cannon, D. L. (2021) · American Journal of Industrial Medicine · doi:10.1002/ajim.23317 · Cited by 3
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III
Witkowski, J., Polak, S., Pawelec, D., & Rogulski, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032239 · Cited by 3
Ethambutol disposition in humans: Challenges and limitations of whole-body physiologically-based pharmacokinetic modelling in early drug development
Carrara, L., Magni, P., Teutonico, D., Pasotti, L., Pasqua, O. E. D., & Kloprogge, F. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105359 · Cited by 3

Authors: Jamei, M.
Affiliations: Simcyp (United Kingdom) (GB)
Corresponding author: Jamei, Masoud
ORCID: Jamei, Masoud
Venue: Current Pharmacology Reports
Publisher: Springer Science and Business Media LLC
Published: 2016-04-14
Volume: 2
Issue: 3
Pages: 161-169
ISSN: 2198-641X (ISSN-L)
DOI: 10.1007/s40495-016-0059-9
PMC: PMC4856711
OpenAlex: W2341647963
Cited by: 244
References: 41
Citations by year: 2026: 10 · 2025: 21 · 2024: 17 · 2023: 29 · 2022: 20 · 2021: 25 · 2020: 31 · 2019: 24 · 2018: 24 · 2017: 37 · 2016: 6
FWCI: 4.70
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (unspecified)
Locations: Current Pharmacology Reports (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: Simcyp Limited (A Certara Company)
Topics: Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords: physiologically based pharmacokinetic modeling, regulatory acceptance, systems pharmacology, precision dosing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks